bezafibrate has been researched along with Disease Exacerbation in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kowdley, KV; Shah, RA | 1 |
| de Veer, RC; Laschtowitz, A; Schramm, C; Van der Meer, AJ | 1 |
| Parés, A; Reig, A; Sesé, P | 1 |
| Suomalainen, A; Yatsuga, S | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A | 1 |
| Ahmed, MH; Osman, KA | 1 |
| Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Haim, M; Matas, Z; Motro, M; Tanne, D; Tenenbaum, A | 1 |
| Adler, Y; Behar, S; Boyko, V; Feinberg, M; Fisman, EZ; Lapidot, M; Matas, Z; Motro, M; Schwammenthal, E; Tanne, D; Tenenbaum, A; Tenenbaum, H | 1 |
| de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 1 |
| Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 1 |
| Ericsson, CG | 1 |
| de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Karpe, F; Nilsson, J; Ruotolo, G; Svane, B; Tettamanti, C | 1 |
| Båvenholm, P; Brismar, K; de Faire, U; Eféndic, S; Ericsson, CG; Hamsten, A; Nilsson, J; Ruotolo, G | 1 |
3 review(s) available for bezafibrate and Disease Exacerbation
| Article | Year |
|---|---|
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
Diagnosis and treatment of primary biliary cholangitis.
Topics: Autoantigens; Autoimmune Diseases; Bezafibrate; Biomarkers; Biopsy; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; End Stage Liver Disease; Fatigue; Female; Humans; Immunoglobulin M; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Middle Aged; Off-Label Use; Prognosis; Pruritus; Quality of Life; Severity of Illness Index; Sjogren's Syndrome; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides | 1998 |
7 trial(s) available for bezafibrate and Disease Exacerbation
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
Topics: Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Homeostasis; Humans; Hypolipidemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Placebos | 2007 |
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Topics: Adult; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Feasibility Studies; Fibrinogen; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Risk Factors; Time Factors; Triglycerides | 1996 |
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Diet, Fat-Restricted; Disease Progression; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Risk Factors; Time Factors | 1997 |
Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Topics: Adult; Bezafibrate; Cholesterol; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Male; Myocardial Infarction; Recurrence; Treatment Outcome; Triglycerides | 1998 |
Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (B
Topics: Adult; Apolipoproteins; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Treatment Outcome | 1998 |
Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Topics: Adult; Bezafibrate; Biomarkers; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypolipidemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Lipoproteins; Male; Myocardial Infarction; Treatment Outcome | 2000 |
4 other study(ies) available for bezafibrate and Disease Exacerbation
| Article | Year |
|---|---|
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Topics: Alkaline Phosphatase; Bezafibrate; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Humans; Hypolipidemic Agents; Jaundice; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Pruritus; Ursodeoxycholic Acid; Visual Analog Scale | 2018 |
Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Temperature; Disease Progression; DNA Helicases; DNA, Mitochondrial; Electron Transport Complex IV; Female; Fibroblast Growth Factors; Hepatomegaly; Lipid Metabolism; Liver; Male; Mice; Mitochondria; Mitochondrial Myopathies; Mitochondrial Proteins; Muscle Fibers, Skeletal; Mutation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisome Proliferator-Activated Receptors; RNA, Messenger; Trans-Activators; Transcription Factors; Weight Loss | 2012 |
Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
Topics: Antineoplastic Agents, Hormonal; Bezafibrate; Breast Neoplasms; Diabetes Complications; Disease Progression; Fatty Liver; Humans; Hypolipidemic Agents; Prognosis; Tamoxifen; Time Factors | 2006 |
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Topics: Aged; Bezafibrate; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; Triglycerides | 2006 |